Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03973866 · ClinicalTrials.gov registry record · NA

Alfapump® System in the Treatment of Refractory or Recurrent Ascites (POSEIDON Study)

A NA study, sponsored by Sequana Medical N.V..

Active
Registry status
NA
Development phase
110
Enrollment target

NCT03973866 is a NA study that is active but no longer recruiting, run by Sequana Medical N.V.. The registered enrollment target is 110 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03973866, a NA study, is active but no longer recruiting, sponsored by Sequana Medical N.V..

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
110 participants
Enrollment target

Study Summary

The POSEIDON study is a multi-center, prospective, single arm, crossover pivotal study enrolling up to 70 pivotal cohort patients and up to 45 additional Roll-in patients with refractory or recurrent ascites at up to 20 sites. Pivotal cohort patients will undergo a 3-month pre-implant observation phase after enrollment, followed by implantation of the alfapump and 24 months of post-implant follow up. An analysis will be conducted to support an application for device approval when a minimum of 40 treated pivotal cohort patients are through 6 months.

Interventions

  • DEVICE Alfapump

Trial Details

FieldValue
Enrollment Target 110 participants
Start Date 2019-09-16
Est. Completion 2024-06-30
Phase NA

Sponsor

Sequana Medical N.V.

2 total trials

What the Registry Record Tells You About NCT03973866

The ClinicalTrials.gov registry entry for NCT03973866 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sequana Medical N.V., which has 2 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Alfapump is the first listed.

NCT03973866 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03973866 about?

NCT03973866 is a clinical study titled "Alfapump® System in the Treatment of Refractory or Recurrent Ascites (POSEIDON Study)". The POSEIDON study is a multi-center, prospective, single arm, crossover pivotal study enrolling up to 70 pivotal cohort patients and up to 45 additional Roll-in patients with refractory or recurrent ascites at up to 20 sites. Pivotal cohort patients will undergo a 3-month pre-implant observation ph...

What is the current status of trial NCT03973866?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 110 participants. The study started on 2019-09-16. Estimated completion is 2024-06-30.

What interventions are being tested in trial NCT03973866?

The interventions under investigation include: Alfapump (DEVICE).

Who is sponsoring clinical trial NCT03973866?

This trial is sponsored by Sequana Medical N.V., which has 2 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.